The ISS National Lab’s MicroQuin 3D Tumor examines the effects of a drug on breast and prostate cancer cells in space.

Feb 2022

Jan 2022
MicroQuin Wins DoD Grant for the Development of Ovarian Cancer Therapeutics 

MicroQuin was awarded a $250k grant from the Department of Defense (DoD) Ovarian Cancer Research Program (OCRP) managed by the office of Congressionally Directed Medical Research Programs.

AUG 2021
MicroQuin Signs Non-Clincal Evaluation Agreement NIH/NIAID 

MicroQuin Announces Preclincial Collaboration with NIAID to Evaluate MicroQuin Therapeutics for the treatment of viral infections.

JUN 2021

MicroQuin's experiments performed aboard the International Space Station have implications for earthbound biopharma development.

JAN 2021
Tellus Bioventures invests in MicroQuin

MicroQuin received investments from Tellus Bioventures. Tellus BioVentures is a biotechnology investment fund focused on early-stage innovation and company formation.

APR 2020
MicroQuin wins second place at South Summit Competition

South Summit is the leading innovation platform bringing together the most innovative startups regardless their industry, development stage and country.

JUL 2019
MicroQuin experiment makes it to the International Space Station

MicroQuin's protein study to be conducted on the ISS was launched on 7/25 aboard SpaceX CRS-18. Read more on NASA's press releases here and here

MAR 2019
MicroQuin and Dr. Scott Robinson featured in Boston Globe

A glimpse into the journey that Dr. Robinson has been on to drive our technology to its current stage. 

Nov 2018
MicroQuin joins prestigious LabCentral in Kendall Square, Cambridge

MicroQuin has been accepted into the highly competitive Lab Central.  We intend to continue our ground breaking research at this facility and strive to make significant advances in delivering first-in-class treatments for breast cancer.  Watch this space!

Oct 2018
MicroQuin is going to space for studies in the International Space Station!

MicroQuin wins TWO grants from CASIS/BOEING under this year’s “Technology in Space” program. For the first time CASIS funded 2 projects from one company as part of its MassChallenge competition. These studies will be performed on the ISS and the data will have considerable impact on creating new scientific approaches to battling cancer.

Sep 2018
MicroQuin was invited to present its ground-breaking technologies

MicroQuin was invited to showcase our high impact and transformational technology at Health Pioneers 2018.  The conference brings together decision-makers and innovators from the pharma, biotech, insurance and public health sectors to explore new ways to collaborate and pioneer. 

Sep 2018
MicroQuin is a winner of the Health Hub Vienna 2018 package

Health Hub Vienna is an acceleration program is managed by INiTS, Vienna’s high-tech incubator with an over 15-year track record of successfully developing start-ups in the life sciences.

Sep 2018
MicroQuin is a Top 26 Finalist of MassChallenge 

The 26 finalists were selected among the 128 early-stage ventures at MassChallenge Boston’s acceleration program in May. The selected companies will move into the final judging round of the MassChallenge Awards, where they’ll compete for shares of $1.5 million in equity-free prizes.